Travere Therapeutics (TVTX) Cash from Discontinued Operations (2022 - 2024)
Travere Therapeutics (TVTX) posted Cash from Discontinued Operations of 7089000.0 for Q4 2024, down 14278.0% on a QoQ basis from 50000.0 in Q3 2024, and down 16.21% year-over-year from 8460751.32 in Q1 2024.
Travere Therapeutics (TVTX) Cash from Discontinued Operations (2022 - 2024) Analysis & Trends
Travere Therapeutics' Cash from Discontinued Operations history runs 3 years deep, the most recent figure standing at 7089000.0 for Q4 2024.
- Quarterly Cash from Discontinued Operations fell 16.21% year-over-year to 7089000.0 in Q4 2024, while the trailing twelve-month figure through Sep 2025 was 7089000.0 (down 9.7% YoY) and the FY2024 annual result came in at 7451000.0, down 116.44% from the prior year.
- Cash from Discontinued Operations was 7089000.0 for Q4 2024 at Travere Therapeutics, down from 50000.0 in the prior quarter.
- Across five years, Cash from Discontinued Operations topped out at 22064000.0 in Q4 2022 and bottomed at 7089000.0 in Q4 2024.
- A 3-year average of 6661000.0 and a median of 50000.0 in 2024 frame the typical range for Cash from Discontinued Operations.
- Annual changes were most pronounced in 2023 — Cash from Discontinued Operations sank 127.65% — and 2024, when it dropped 16.21%.
- Travere Therapeutics' Cash from Discontinued Operations stood at 22064000.0 in 2022, then sank by 127.65% to 6100000.0 in 2023, then retreated by 16.21% to 7089000.0 in 2024.
- Business Quant data shows TVTX's Cash from Discontinued Operations at 7089000.0 in Q4 2024, 50000.0 in Q3 2024, and 309000.0 in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Discontinued Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Travere Therapeutics | 5.24 Bn | 5.24 Bn | 125.25 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -7.09 Mn |
| Dec 31, 2024 | -7.09 Mn |
| Sep 30, 2024 | 50,000.00 |
| Sep 30, 2024 | 50,000.00 |
| Jun 30, 2024 | -309,000.00 |
| Jun 30, 2024 | -309,000.00 |
| Mar 31, 2024 | -103,000.00 |
| Mar 31, 2024 | -103,000.00 |
| Dec 31, 2023 | -6.10 Mn |
| Dec 31, 2023 | -6.10 Mn |
| Sep 30, 2023 | 15.29 Mn |
| Sep 30, 2023 | 15.29 Mn |
| Jun 30, 2023 | 18.61 Mn |
| Jun 30, 2023 | 18.61 Mn |
| Mar 31, 2023 | 17.53 Mn |
| Mar 31, 2023 | 17.53 Mn |
| Dec 31, 2022 | 22.06 Mn |
| Dec 31, 2022 | 22.06 Mn |